Opinion

Video

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

Author(s):

Elizabeth R. Plimack, MD, MS, FASCO,Neeraj Agarwal, MD

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Related Videos
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Chad Tang, MD
Jared Weiss, MD
5 KOLs are featured in this series.
Related Content
Douglas W. Sborov, MD, MS
October 28th 2024

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Allison A. Aggon, DO, FACOS, Associate Professor, Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center
October 24th 2024

Fox Chase Cancer Center’s Dr. Allision Aggon Receives Earth Angel Award From Breast Cancer Nonprofit Organization

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Alan Tan, MD
October 18th 2024

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

Neeraj Agarwal, MD, FASCO
October 17th 2024

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC